公开(公告)号：US20210030734A1

公开(公告)日：2021-02-04

申请号：US17076069

申请日：2020-10-21

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michal GEVA ,  Michael Hayden

IPC: A61K31/451 ,  A61P25/28 ,  A61K9/00

Abstract: Provided herein is a method for treating a human subject afflicted with ALS by administering to the subject a therapeutically effective amount of pridopidine.

公开(公告)号：US20210052560A1

公开(公告)日：2021-02-25

申请号：US17019346

申请日：2020-09-13

Applicant: PRILENIA NEUROTHERAPEUTICS LTD.

Inventor： Michael Hayden ,  Michal Geva

IPC: A61K31/44 ,  A61K9/48 ,  A61P25/14

Abstract: This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.